Stimulus-responsive hybrid nanoparticles based on multiple lipids for the co-delivery of doxorubicin and Sphk2-siRNA and breast cancer therapy.

The development of breast cancer is usually related to multiple pathways. A combinatory therapeutic system that combines drug/siRNA targeting several independent pathways has become an attractive approach to reduce the side effects and improve the efficiency of antitumor drugs. Herein, we designed a unique micelle-liposome hybrid nanoparticle platform for the combinatory administration of the cytotoxic drug DOX and Sphk2-siRNA for the treatment of multidrug-resistant (MDR) cancer. The synthesized lipid dioleoyl ethanolamine (DE) and pH-responsive DOPE were used to produce DOX/siRNA co-loaded hybrid nanoparticle (DOX-MC-siSphk2/ASLNP), with high drug-loading capacity and transfection efficacy. We demonstrated that simultaneous cellular endocytosis of DOX/siRNA induced by nanoparticles in MCF-7/ADR cells could acquire higher drug cytotoxicity and contribute to increasing the apoptosis of tumor cell. Furthermore, DOX-MC-siSphk2/ASLNP could significantly block the tumor growth of MDR breast cancer in xenograft mouse model with lower cardiotoxicity.